Cardiac hypertrophy is not amplified by deletion of cGMP-dependent protein kinase I in cardiomyocytes

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 12, 2010, Pages 5646-5651

  Lukowski, Robert ^a,c   Rybalkin, Sergei D ^a,b,d   Loga, Florian ^a,b   Leiss, Veronika ^a,b   Beavo, Joseph A ^a,b,d   Hofmann, Franz ^a,b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Cyclic nucleotides; Phosphodiesterase; Phosphorylation; Sildenafil; Transverse aortic constriction

Indexed keywords

ATRIAL NATRIURETIC FACTOR; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; CYCLIC GMP DEPENDENT PROTEIN KINASE 1; ISOPRENALINE; PHOSPHODIESTERASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA CONSTRICTION; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; GENOTYPE; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; KNOCKOUT MOUSE; LONG TERM EXPOSURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; WILD TYPE;

ANIMALS; BASE SEQUENCE; CARDIOMEGALY; CELLS, CULTURED; CYCLIC GMP-DEPENDENT PROTEIN KINASES; DNA PRIMERS; GENE EXPRESSION; ISOPROTERENOL; MICE; MICE, KNOCKOUT; MODELS, CARDIOVASCULAR; MYOCYTES, CARDIAC; MYOCYTES, SMOOTH MUSCLE; RNA, MESSENGER; SIGNAL TRANSDUCTION;

MUS;

EID: 77950377332     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1001360107     Document Type: Article

References (61)

1. Nishikimi T, Maeda N, Matsuoka H (2006) The role of natriuretic peptides in cardioprotection. Cardiovasc Res 69:318-328.
2. Oliver PM, et al. (1997) Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. Proc Natl Acad Sci USA 94:14730-14735.
3. Lopez MJ, et al. (1995) Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide. Nature 378:65-68.
4. Knowles JW, et al. (2001) Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice. J Clin Invest 107:975-984.
5. Kishimoto I, Rossi K, Garbers DL (2001) A genetic model provides evidence that the receptor for atrial natriuretic peptide (guanylyl cyclase-A) inhibits cardiac ventricular myocyte hypertrophy. Proc Natl Acad Sci USA 98:2703-2706. (Pubitemid 32209546)
6. Holtwick R, et al. (2003) Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A. J Clin Invest 111:1399-1407. (Pubitemid 36554711)
7. Calderone A, Thaik CM, Takahashi N, Chang DL, Colucci WS (1998) Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. J Clin Invest 101:812-818. (Pubitemid 28096078)
8. Horio T, et al. (2000) Inhibitory regulation of hypertrophy by endogenous atrial natriuretic peptide in cultured cardiac myocytes. Hypertension 35:19-24. (Pubitemid 30054231)
9. Ellmers LJ, et al. (2007) Npr1-regulated gene pathways contributing to cardiac hypertrophy and fibrosis. J Mol Endocrinol 38:245-257.
10. John SW, et al. (1995) Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension. Science 267:679-681.
11. Franco V, et al. (2004) Atrial natriuretic peptide dose-dependently inhibits pressure overload-induced cardiac remodeling. Hypertension 44:746-750. (Pubitemid 39435248)
12. Mori T, et al. (2004) Volume overload results in exaggerated cardiac hypertrophy in the atrial natriuretic peptide knockout mouse. Cardiovasc Res 61:771-779.
13. Langenickel TH, et al. (2006) Cardiac hypertrophy in transgenic rats expressing a dominant-negative mutant of the natriuretic peptide receptor B. Proc Natl Acad Sci USA 103:4735-4740.
14. Li P, et al. (2008) Atrial natriuretic peptide inhibits transforming growth factor beta-induced Smad signaling and myofibroblast transformation in mouse cardiac fibroblasts. Circ Res 102:185-192.
15. Maki T, et al. (2000) Effect of neutral endopeptidase inhibitor on endogenous atrial natriuretic peptide as a paracrine factor in cultured cardiac fibroblasts. Br J Pharmacol 131:1204-1210.
16. Brown RD, Ambler SK, Mitchell MD, Long CS (2005) The cardiac fibroblast: Therapeutic target in myocardial remodeling and failure. Annu Rev Pharmacol Toxicol 45:657-687. (Pubitemid 40261821)
17. Kumar R, Joyner RW, Komalavilas P, Lincoln TM (1999) Analysis of expression of cGMP-dependent protein kinase in rabbit heart cells. J Pharmacol Exp Ther 291: 967-975.
18. Wegener JW, et al. (2002) cGMP-dependent protein kinase I mediates the negative inotropic effect of cGMP in the murine myocardium. Circ Res 90:18-20. (Pubitemid 34074603)
19. Fiedler B, et al. (2006) cGMP-dependent protein kinase type I inhibits TAB1-p38 mitogen-activated protein kinase apoptosis signaling in cardiac myocytes. J Biol Chem 281:32831-32840. (Pubitemid 46036838)
20. Fiedler B, et al. (2002) Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes. Proc Natl Acad Sci USA 99: 11363-11368.
21. Costa AD, et al. (2005) Protein kinase G transmits the cardioprotective signal from cytosol to mitochondria. Circ Res 97:329-336.
22. Ecker T, et al. (1989) Decreased cardiac concentration of cGMP kinase in hypertensive animals. An index for cardiac vascularization? Circ Res 65:1361-1369.
23. Kass DA, Champion HC, Beavo JA (2007) Phosphodiesterase type 5: Expanding roles in cardiovascular regulation. Circ Res 101:1084-1095.
24. Conti M, Beavo J (2007) Biochemistry and physiology of cyclic nucleotide phosphodiesterases: Essential components in cyclic nucleotide signaling. Annu Rev Biochem 76:481-511.
25. Stein B, et al. (1996) Relation between contractile function and regulatory cardiac proteins in hypertrophied hearts. Am J Physiol 270:H2021-H2028. (Pubitemid 126833607)
26. Marks AR (2000) Cardiac intracellular calcium release channels: Role in heart failure. Circ Res 87:8-11. (Pubitemid 30456928)
27. Ziolo MT, Lewandowski SJ, Smith JM, Romano FD, Wahler GM (2003) Inhibition of cyclic GMP hydrolysis with zaprinast reduces basal and cyclic AMP-elevated L-type calcium current in guinea-pig ventricular myocytes. Br J Pharmacol 138:986-994.
28. Ono K, Trautwein W (1991) Potentiation by cyclic GMP of beta-adrenergic effect on Ca2+ current in guinea-pig ventricular cells. J Physiol (Lond) 443:387-404.
29. Zimmer HG (1997) Catecholamine-induced cardiac hypertrophy: Significance of protooncogene expression. J Mol Med 75:849-859. (Pubitemid 27511561)
30. Métrich M, et al. (2008) Epac mediates beta-adrenergic receptor-induced cardiomyocyte hypertrophy. Circ Res 102:959-965.
31. Lewin G, et al. (2009) Critical role of transcription factor cyclic AMP response element modulator in beta1-adrenoceptor-mediated cardiac dysfunction. Circulation 119:79-88.
32. Balligand JL, et al. (1995) Nitric oxide-dependent parasympathetic signaling is due to activation of constitutive endothelial (type III) nitric oxide synthase in cardiac myocytes. J Biol Chem 270:14582-14586.
33. Takimoto E, et al. (2005) cGMP catabolism by phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3-dependent mechanism. Circ Res 96:100-109. (Pubitemid 40095759)
34. Takimoto E, et al. (2005) Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 11:214-222. (Pubitemid 40321358)
35. Nagayama T, et al. (2009) Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload. J Am Coll Cardiol 53: 207-215.
36. Schröder F, et al. (2003) Single L-type Ca(2+) channel regulation by cGMP-dependent protein kinase type I in adult cardiomyocytes from PKG I transgenic mice. Cardiovasc Res 60:268-277. (Pubitemid 37412360)
37. Moens AL, et al. (2008) Reversal of cardiac hypertrophy and fibrosis from pressure overload by tetrahydrobiopterin: Efficacy of recoupling nitric oxide synthase as a therapeutic strategy. Circulation 117:2626-2636.
38. Wollert KC, et al. (2002) Gene transfer of cGMP-dependent protein kinase I enhances the antihypertrophic effects of nitric oxide in cardiomyocytes. Hypertension 39:87-92.
39. Méry PF, Pavoine C, Belhassen L, Pecker F, Fischmeister R (1993) Nitricoxide regulates cardiac Ca2+ current. Involvement of cGMP-inhibited and cGMP-stimulated phosphodiesterases through guanylyl cyclase activation. J Biol Chem 268:26286-26295.
40. Kilic A, et al. (2005) Enhanced activity of the myocardial Na+/H+ exchanger NHE-1 contributes to cardiac remodeling in atrial natriuretic peptide receptor-deficient mice. Circulation 112:2307-2317. (Pubitemid 41464574)
41. Kato T, et al. (2005) Atrial natriuretic peptide promotes cardiomyocyte survival by cGMP-dependent nuclear accumulation of zyxin and Akt. J Clin Invest 115:2716-2730. (Pubitemid 41434399)
42. Krüger M, et al. (2009) Protein kinase G modulates human myocardial passive stiffness by phosphorylation of the titin springs. Circ Res 104:87-94.
43. Weber S, et al. (2007) Rescue of cGMP kinase I knockout mice by smooth muscle specific expression of either isozyme. Circ Res 101:1096-1103. (Pubitemid 350146435)
44. Burley DS, Ferdinandy P, Baxter GF (2007) Cyclic GMP and protein kinase-G in myocardial ischaemia-reperfusion: Opportunities and obstacles for survival signaling. Br J Pharmacol 152:855-869. (Pubitemid 350100488)
45. Heusch G, Boengler K, Schulz R (2008) Cardioprotection: Nitric oxide, protein kinases, and mitochondria. Circulation 118:1915-1919.
46. Pfeifer A, et al. (1998) Defective smooth muscle regulation in cGMP kinase I-deficient mice. EMBO J 17:3045-3051. (Pubitemid 28254377)
47. Geiselhöringer A, Gaisa M, Hofmann F, Schlossmann J (2004) Distribution of IRAG and cGKI-isoforms in murine tissues. FEBS Lett 575:19-22. (Pubitemid 39237675)
48. Butt E, et al. (1994) cAMP- and cGMP-dependent protein kinase phosphorylation sites of the focal adhesion vasodilator-stimulated phosphoprotein (VASP) in vitro and in intact human platelets. J Biol Chem 269:14509-14517. (Pubitemid 24194005)
49. Iaccarino G, Dolber PC, Lefkowitz RJ, Koch WJ (1999) Beta-adrenergic receptor kinase-1 levels in catecholamine-induced myocardial hypertrophy: Regulation by beta- but not alpha1-adrenergic stimulation. Hypertension 33:396-401. (Pubitemid 29065691)
50. Engelhardt S, Hein L, Wiesmann F, Lohse MJ (1999) Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. Proc Natl Acad Sci USA 96: 7059-7064. (Pubitemid 29275009)
51. Antos CL, et al. (2002) Activated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivo. Proc Natl Acad Sci USA 99:907-912.
52. Takimoto E, et al. (2009) Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice. J Clin Invest 119:408-420.
53. Tsai EJ, Kass DA (2009) Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. Pharmacol Ther 122:216-238.
54. Pokreisz P, et al. (2009) Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice. Circulation 119:408-416.
55. Wettschureck N, et al. (2001) Absence of pressure overload induced myocardial hypertrophy after conditional inactivation of Galphaq/Galpha11 in cardiomyocytes. Nat Med 7:1236-1240. (Pubitemid 33063779)
56. Harada K, et al. (1998) Pressure overload induces cardiac hypertrophy in angiotensin II type 1A receptor knockout mice. Circulation 97:1952-1959. (Pubitemid 28222190)
57. Crowley SD, et al. (2006) Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci USA 103:17985-17990.
58. Vandeput F, et al. (2007) Cyclic nucleotide phosphodiesterase PDE1C1 in human cardiac myocytes. J Biol Chem 282:32749-32757. (Pubitemid 350159317)
59. Vandeput F, et al. (2009) cGMP-hydrolytic activity and its inhibition by sildenafil in normal and failing human and mouse myocardium. J Pharmacol Exp Ther 330: 884-891.
60. Lukowski R, et al. (2008) Role of smooth muscle cGMP/cGKI signaling in murine vascular restenosis. Arterioscler Thromb Vasc Biol 28:1244-1250.
61. Qiu P, Feng XH, Li L (2003) Interaction of Smad3 and SRF-associated complex mediates TGF-beta1 signals to regulate SM22 transcription during myofibroblast differentiation. J Mol Cell Cardiol 35:1407-1420. (Pubitemid 37491184)